Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408623 | 1.00 | CA2 (0.39) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL6575029 | 0.87 | CA2 (0.38) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL6574569 | 0.86 | CA2 (0.36) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL6576759 | 0.84 | CA2 (0.34) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL23499229 | 0.83 | CA2 (0.39) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL23518792 | 0.83 | CA2 (0.39) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7213941 | 0.82 | CA2 (0.43) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL23499267 | 0.81 | CA2 (0.37) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL20091180 | 0.81 | CA2 (0.41) | CA2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL30760678 | 0.80 | MAPT (0.37) | CA2KMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292604-B1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7094769-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2006-06-08 | — | — | US | disclosed |
| EP-1255764-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2006-05-10 | — | — | EP | disclosed |
| EP-1220862-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-6753322-B2 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-06-22 | — | — | US | disclosed |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PFIZER INC | 2004-04-22 | — | — | US | disclosed |
| EP-1292604-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-03-19 | — | — | EP | disclosed |
| US-6525032-B2 | Agonists of human adenosine receptors useful as anti-inflammatory agents in treatment of diseases of respiratory tract; chemical intermediates | PFIZER INC | 2003-02-25 | — | — | US | disclosed |
| US-6448236-B1 | FUNCTIONAL AGONISTS OF THE HUMAN ADENOSINE A2A RECEPTOR AND MAY BE USED AS, FOR EXAMPLE, ANTI-INFLAMMATORY AGENTS IN THE TREATMENT OF REPIRATORY DISEASES | PFIZER INC | 2002-09-10 | — | — | US | disclosed |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001094368-A1 | 2-AMINOCARBONYL-9H-PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-12-13 | — | — | WO | disclosed |
| US-20010020089-A1 | Purine derivatives | PFIZER INC. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020089-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CA2 2581/4885KMT2A 4222/4885ALDH1A1 383/4885 |
| US-20060122145-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | CA2 2747/4885KMT2A 2593/4885ALDH1A1 533/4885 |
| US-20040077584-A1 | 2-Aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A2 | CA2 2728/4885KMT2A 2578/4885ALDH1A1 385/4885 |
| US-20020058641-A1 | 2-aminocarbonyl-9H-purine derivatives | PNP, NUDT1, SLC29A1 | CA2 2796/4885KMT2A 3004/4885ALDH1A1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.